ClinicalTrials.gg
CompletedNCT00261092Updated Apr 15, 2008

GEMOX: Oxaliplatin in Pancreatic Cancer

A Phase 2 interventional study of Oxaliplatin in Pancreatic Neoplasms, sponsored by Sanofi. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-04-15.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies testing oxaliplatin in Pancreatic Neoplasms — 13 open to participants now, 19 under way, 7 of them phase 3. Oxaliplatin · Pancreatic Neoplasms.

Enrollment
39th of 83
48 · median 46
Started
2005
with 5 others
Phase 2
47 of 88
7 open now
Registered
15th of 88
by date
Lead sponsor
2 of 88
Sanofi

Among the 88 studies testing oxaliplatin in Pancreatic Neoplasms, this one is the 39th largest by enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2005, is one of 47 in phase 2, and was the 15th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

13 of the 88 studies testing oxaliplatin in Pancreatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies testing oxaliplatin in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

Primary objective:

  • To evaluate overall response rate (based on RECIST criterion)

Secondary objective:

  • To evaluate time to progression, clinical benefit, quality of life and safety
03

Conditions studied

  • Pancreatic Neoplasms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the pancreas
  • or locally advanced, non resectable disease(Non resectable disease will be determined by the investigators with clinical data)
  • Uni-dimensionally as defined by (primary or secondary tumors>2cm using conventional CT scan or ≥1cm with spiral CT scan)
  • No previous chemo or radiotherapy, but postoperative radiotherapy as a therapy for non-target lesion is permitted
  • Performance Status (KPS) ≥60
  • No known Central Nervous System metastases
  • No sensory neuropathy at inclusion
  • Biological and hematological evaluation \< 2 weeks prior to treatment administration:

    • Neutrophils ≥ 1500/ mm3
    • ≥ 100,000/mm3
    • Alkaline phosphatases\< 5X (upper Limits of Normal) and \< 1.5X ULN
    • ,SGPT \<2.5 X ULN if no liver metastasis
    • SGOT,SGPT \<5 X ULN if liver metastasis
    • Creatinine \< 1.5 X ULN
  • Baseline imaging (CT scan or Magnetic Resonance Imaging) \<3 weeks before treatment administration
  • Men and women who are fertile must use a medically acceptable throughout the treatment period and for 3 months following cessation of treatment with oxaliplatin. Subjects must be made aware, before entering this trial of the risk of becoming pregnant or in fathering children

Exclusion criteria

Exclusion Criteria:

  • Corticotherapy except for anti-emetic purpose
  • Pregnant or breast feeding women (Documentation of a negative pregnancy test must be available for premenopausal women with intact reproductive organs)
  • Uncontrolled congestive heart failure or angina pectoris, or hypertension or arrhythmia
  • Uncontrolled or persistent hypercalcemia
  • History of significant neurologic or psychiatric disorders
  • Vater ampulomas and biliary tract adenocarcinomas
  • Other -non cured-

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Overall response rate based on RECIST criteria

Secondary outcomes

  1. Time to progression

  2. Overall survival

  3. Clinical benefit

  4. Quality of life

07

Study locations

1 site
  • Sanofi-Aventis
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00261092
Lead sponsor
Sanofi
First posted
Dec 2, 2005
Start date
Oct 2005
Last update
Apr 15, 2008

Study contacts

Won-Sik Lee, MD
study director · sanofi-avents
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxaliplatin

Start the discussion